Research Analysts’ Recent Ratings Updates for Aligos Therapeutics (ALGS)

A number of research firms have changed their ratings and price targets for Aligos Therapeutics (NASDAQ: ALGS):

• 5/29/2026 – Aligos Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 5/28/2026 – Aligos Therapeutics is now covered by Lake Street Capital. They set a “buy” rating and a $45.00 price target on the stock.
• 5/21/2026 – Aligos Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $20.00 price target on the stock.
• 5/21/2026 – Aligos Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $20.00 price target on the stock.
• 5/17/2026 – Aligos Therapeutics was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 5/9/2026 – Aligos Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 4/20/2026 – Aligos Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.